Connect Biopharma (CNTB) Stock Forecast, Price Target & Predictions
CNTB Stock Forecast
Connect Biopharma stock forecast is as follows: an average price target of $1.50 (represents a 51.50% upside from CNTB’s last price of $0.99) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CNTB Price Target
The average price target for Connect Biopharma (CNTB) is $1.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 51.50% upside from CNTB's last price of $0.99.
CNTB Analyst Ratings
According to 2 Wall Street analysts, Connect Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for CNTB stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Connect Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 05, 2022 | Joseph Catanzaro | Piper Sandler | $1.50 | $0.82 | 82.88% | 51.50% |
The latest Connect Biopharma stock forecast, released on May 05, 2022 by Joseph Catanzaro from Piper Sandler, set a price target of $1.50, which represents a 82.88% increase from the stock price at the time of the forecast ($0.82), and a 51.50% increase from CNTB last price ($0.99).
Connect Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.99 | $0.99 | $0.99 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Connect Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Connect Biopharma's last price of $0.99. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Connect Biopharma's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave CNTB a "Buy" rating, the same as its previous rate.
Connect Biopharma Financial Forecast
Connect Biopharma Revenue Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | $12.06M | $1.10B | $1.06B |
| High Forecast | $12.06M | $1.10B | $1.06B |
| Low Forecast | $12.06M | $1.10B | $1.06B |
| # Analysts | 1 | 1 | 1 |
| Surprise % | - | - | - |
Connect Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Connect Biopharma EBITDA Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict CNTB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Connect Biopharma's previous annual EBITDA (undefined) of $NaN.
Connect Biopharma Net Income Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| Net Income | - | - | - |
| Avg Forecast | $600.89M | $-81.35M | $-89.68M |
| High Forecast | $600.89M | $-81.35M | $-89.68M |
| Low Forecast | $600.89M | $-81.35M | $-89.68M |
| Surprise % | - | - | - |
Connect Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Connect Biopharma SG&A Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Connect Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTB last annual SG&A of $NaN (undefined).
Connect Biopharma EPS Forecast
| Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|
| # Analysts | 1 | 1 | 1 |
| EPS | - | - | - |
| Avg Forecast | $10.82 | $-1.46 | $-1.61 |
| High Forecast | $10.82 | $-1.46 | $-1.61 |
| Low Forecast | $10.82 | $-1.46 | $-1.61 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Connect Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTB previous annual EPS of $NaN (undefined).
Connect Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OVID | Ovid Therapeutics | $1.06 | $7.33 | 591.51% | Buy |
| CTMX | CytomX Therapeutics | $0.87 | $5.73 | 558.62% | Buy |
| TIL | Instil Bio | $24.76 | $78.25 | 216.03% | Hold |
| NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
| ASMB | Assembly Biosciences | $14.72 | $35.50 | 141.17% | Buy |
| NXTC | NextCure | $1.29 | $3.00 | 132.56% | Buy |
| ACHL | Achilles Therapeutics | $1.07 | $2.00 | 86.92% | Buy |
| CNTB | Connect Biopharma | $0.99 | $1.50 | 51.52% | Buy |